The shingles vaccine may reduce the risk of dementia
Points and comments are a snapshot, not live.
A new study shows the shingles vaccine may cut dementia risk by 20%, but many health systems balk at the cost.
The Economist argues the shingles vaccine may dramatically reduce dementia risk, citing research suggesting a 20% risk reduction. However, many countries' health systems focus on the upfront cost of around $300 per dose and do not recommend it for all eligible adults.
The article contrasts this with other protective factors like anti-depression treatment, education, hearing improvement, obesity reduction, and low alcohol consumption. The vaccination's simplicity makes it a standout public health intervention, but age-based recommendations (e.g., age 50 in the US) prevent earlier uptake.
What commenters are saying
Commenters widely accept the 20% risk reduction but note the age cutoff is frustrating for those under 50. Several users report getting shingles in their 30s or 40s, describing it as extremely painful and urging others not to wait.
Two camps emerge: those who argue for getting the vaccine early (even paying out of pocket) to get the dementia benefit sooner, and those who say protection may wane if taken too early, making age-50 timing optimal. A key pro-tip: in the US, you can get the vaccine early if you have a qualifying condition like type 2 diabetes.